Director Wang Jing from the Dermatology and Medical Aesthetics Department of Shenzhen New Frontier United Family Hospital is treating patients.

 

On January 8th, Shenzhen New Frontier United Family Hospital issued its first prescription for the world's first new drug for vitiligo, Lucretinib, which was approved after being listed as a designated medical institution under the "Hong Kong Macau Medical Device Connect". The landing of the first drug marks an important breakthrough for the hospital in cross-border medical services and innovative drug and equipment introduction, while also providing new treatment options for vitiligo patients.

Vitiligo is an acquired local or systemic depigmentation skin disease characterized by white patches of different sizes and shapes on the skin, commonly found on the face, neck, hands, limbs, back, and other areas. It affects approximately 0.5-2% of the global population and has a very high proportion of patients. According to statistics, at present, the number of vitiligo patients in China has climbed to tens of millions, and the incidence rate has increased in the past decade.

Shenzhen New Frontier United Family Hospital, as one of the designated medical institutions in the Guangdong Hong Kong Macao Greater Bay Area's "Hong Kong Macao Drug and Device Connect", actively introduces innovative drugs and devices that are urgently needed in clinical practice and have already been listed in Hong Kong and Macao. The introduction of Lucretinib Phosphate Cream this time is an important measure taken by the hospital to actively respond to policy requirements and provide patients with more comprehensive and efficient innovative medical services.

 

The world's first new drug for vitiligo, Lucretinib. (Photo by journalist Guo Ruoxi)

Director Wang Jing of the Dermatology and Medical Aesthetics Department at Shenzhen New Frontier United Family Hospital stated that currently vitiligo patients often choose oral medication, phototherapy, or autologous epidermal transplantation for treatment. However, long-term use of oral medication may cause burden and damage to the liver and kidneys. Long term phototherapy or excessive irradiation can increase the risk of skin damage. As a surgical procedure, autologous epidermal transplantation carries risks such as infection, scarring, and postoperative reactions. Due to the potential impact of vitiligo on the psychological and emotional well-being of patients, the uncertainty and fluctuations in treatment outcomes may increase the psychological burden.

The first and currently the only topical treatment for vitiligo, approved by the Guangdong Provincial Drug Administration, is the application of Lucretinib Phosphate Cream JAK Inhibitors, whose principle of action is to inhibit the signaling pathways that mediate multiple cytokines and growth factors JAK1 and JAK2， Reduce melanocyte specificity in the skin CD8+T Cells provide an environment for the recovery of melanocytes, thereby playing a role in color reproduction.

Ms. Xia has been suffering from vitiligo for less than a year, and the white patches mainly appear on her face and palms, which affects her appearance. Therefore, she urgently hopes to seek effective treatment. Prior to this, Ms. Xia had tried various methods of treatment, including topical medication, phototherapy, and traditional Chinese medicine treatment, but the results were not satisfactory. She learned that Shenzhen New Frontier United Family Hospital could purchase Lukotinib cream and hoped to try new drugs to improve her condition.

Director Wang Jing stated that for the treatment of vitiligo patients, the use of Lukotinib cream is simple. It only needs to be gently applied twice a day on the affected skin, with an interval of more than 8 hours between each application. After using the cream, at least 2 hours should be avoided from cleaning the skin at the application site. At the same time, as an external cream, Lucretinib is convenient to use and helps improve the treatment compliance and quality of life of vitiligo patients.

 

Shi Ying, Director of the Pharmacy Department at Shenzhen New Frontier United Family Hospital.

Shi Ying, Director of the Pharmacy Department at Shenzhen New Frontier United Family Hospital, stated that this drug provides an additional option for clinical doctors and patients in the treatment of vitiligo. The hospital will continue to actively introduce more innovative drugs and devices that are urgently needed in clinical practice and have been listed in Hong Kong and Macau, based on the needs of patients. It will quickly and conveniently share global pharmaceutical innovation achievements and provide more comprehensive and efficient innovative medical services for residents in the Bay Area.

【 Media Source - Wen Hui Bao 】

https://www.wenweipo.com/a/202501/08/AP677e4030e4b0cb90986d1ce0.html